Protocol Ledger

NCT07215910 · Phase III · RECRUITING

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

Interventional Phase III clinical trial protocol NCT07215910 sponsored by Alliance for Clinical Trials in Oncology in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-06-24 Enrollment: 408 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07215910
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)408 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07215910
Protocol FieldVerified Registry Value
NCT IdentifierNCT07215910
Consolidated Lead SponsorAlliance for Clinical Trials in Oncology
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment408 participants (ESTIMATED)
Registered Start Date2026-06-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07215910
Hospital Research SiteLocationSite Profile
Kaiser Permanente-AnaheimAnaheim, CAOpen Hospital Dossier ->
Kaiser Permanente-BellflowerBellflower, CAOpen Hospital Dossier ->
City of Hope National Medical CenterDuarte, CAOpen Hospital Dossier ->
Kaiser Permanente DublinDublin, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI